Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States

摘要: The antiretroviral combination of emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) was approved by the U.S. Food and Drug Administration for use as pre-exposure prophylaxis (PrEP) in individuals at high risk acquiring human immunodeficiency virus (HIV) July 2012. Since then, Centers Disease Control Prevention guidelines PrEP have been published implemented into clinical practice throughout United States. A number open-label demonstration projects evaluated real-world including analysis barriers to its addressing major concerns. Despite approval FTC/TDF PrEP, this indication relies on patient provider acceptance, effectiveness requires adherence retention care during periods high-risk behaviors. Concerns regarding healthy persist include medication adverse effects renal dysfunction bone mineral density loss; compensation leading HIV infections, sexually transmitted unintended pregnancies; development drug resistance event seroconversion. cost-effectiveness continues be assessed with greatest remaining those highest HIV. Additionally, cases acquisition who are adherent highlight scenarios which is not 100% effective against transmission drug-resistant strains. This review examines data implementation outside setting trials aim providing clinicians a summary current opportunities specific focus role pharmacists optimization implementation.